Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.For licensed clinicians. Educational demonstration on synthetic data. Never enter real patient identifiers or protected health information: everything runs in your browser and nothing is sent or stored. Clinical decision support only; not FDA cleared; physician review is required.
CPE-007 · Risk category
CV-01: Established ASCVD
Established ASCVD. Evaluates clinical ASCVD documented (prior myocardial infarction, acute coronary syndrome, ischemic stroke or TIA, symptomatic peripheral arterial disease, revascularization).
Condition
- clinical ASCVD documented (prior myocardial infarction, acute coronary syndrome, ischemic stroke or TIA, symptomatic peripheral arterial disease, revascularization)
What it reports
- Secondary prevention: LDL-C lowering is a cornerstone
- Very high risk when two or more major ASCVD events, or one major event with two or more high-risk conditions
Recommended next steps (for physician review)
- Use the 2022 ACC pathway thresholds for adding non-statin therapy (LDL-C 55 mg/dL for very high risk, 70 otherwise)
Diagnostic boundary
- A category, not a treatment order.
Evidence
- EV-ACCAHA-CHOL-2018Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143.Supports: Risk categories, risk enhancers, statin benefit groups and the coronary-calcium decision aid Very-high-risk ASCVD definition
- EV-ACC-ECDP-2022Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk. J Am Coll Cardiol. 2022;80(14):1366-1418.Supports: LDL-C thresholds of 55 and 70 mg/dL for considering added therapy in ASCVD
Cases where this rule fires
Open a case to see this rule fire with real inputs, then change the values until it stops.
Try Biod in your practice
The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.